Immune checkpoints as therapeutic targets in autoimmunity
Antibodies that block the immune checkpoint receptors PD1 and CTLA4 have revolutionized the treatment of melanoma and several other cancers, but in the process, a new class of drug side effect has emerged-immune related adverse events. The observation that therapeutic blockade of these inhibitory re...
主要な著者: | Paluch, C, Santos, A, Anzilotti, C, Cornall, R, Davis, S |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
Frontiers Media
2018
|
類似資料
-
Immune Checkpoints as Therapeutic Targets in Autoimmunity
著者:: Christopher Paluch, 等
出版事項: (2018-10-01) -
Immune Checkpoints, a Novel Class of Therapeutic Targets for Autoimmune Diseases
著者:: Yujia Zhai, 等
出版事項: (2021-04-01) -
Combination CD200R/PD-1 blockade in a humanised mouse model
著者:: Fellermeyer, M, 等
出版事項: (2023) -
Manipulating immune checkpoint signalling pathways with antibodies
著者:: Paluch, C
出版事項: (2019) -
Dermatological Autoimmune Considerations of Immune Checkpoint Therapy
著者:: Lauren S. Fane, 等
出版事項: (2022-09-01)